Biopharmaceutical research companies are conducting or have conducted nearly 2,000 clinical trials of new medicines in collaboration with the state’s university medical schools, clinical research centers and hospitals (1999 to present).
Of the nearly 2,000 clinical trials, 1,019 target the nation’s six most debilitating chronic diseases— asthma, cancer, diabetes, heart disease, mental illnesses and stroke.
“Clinical trials of new medicines conducted by biopharmaceutical research companies in Nebraska have benefited not only patients, but also the state’s economy. The companies have conducted nearly 2,000 clinical trials in the state since 1999 and by and large, those trials involve collaboration with prominent local research institutions, such as the Fred & Pamela Buffett Cancer Center at the University of Nebraska Medical Center as well as Creighton University School of Medicine and Nebraska Methodist Hospital in Omaha. This research is a revenue source and provides talented Nebraska clinicians the opportunity to work on cutting- edge pharmaceutical development projects that address global healthcare challenges.” --Phil Kozera, Executive Director, Bio Nebraska Life Sciences Association